Vered Bisker-Leib Ph.D., MBA
Net Worth
Last updated:
What is Vered Bisker-Leib Ph.D., MBA net worth?
The estimated net worth of Dr. Vered Bisker-Leib Ph.D., MBA is at least $4,655,518 as of 25 Nov 2022. He owns shares worth $2,894,824 as insider, has earned $200,694 from insider trading and has received compensation worth at least $1,560,000 in Compass Therapeutics, Inc..
What is the salary of Vered Bisker-Leib Ph.D., MBA?
Dr. Vered Bisker-Leib Ph.D., MBA salary is $520,000 per year as Pres & Chief Operating Officer in Compass Therapeutics, Inc..
How old is Vered Bisker-Leib Ph.D., MBA?
Dr. Vered Bisker-Leib Ph.D., MBA is 54 years old, born in 1971.
What stocks does Vered Bisker-Leib Ph.D., MBA currently own?
As insider, Dr. Vered Bisker-Leib Ph.D., MBA owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | Pres & Chief Operating Officer | 1,060,414 | $2.73 | $2,894,824 |
What does Compass Therapeutics, Inc. do?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Vered Bisker-Leib Ph.D., MBA insider trading
Compass Therapeutics, Inc.
Dr. Vered Bisker-Leib Ph.D., MBA has made 5 insider trades in 2022, according to the Form 4 filled with the SEC. Most recently he sold 2 units of CMPX stock worth $9 on 25 Nov 2022.
The largest trade he's ever made was exercising 16,035 units of CMPX stock on 21 Nov 2022. As of 25 Nov 2022 he still owns at least 1,060,414 units of CMPX stock.
Compass Therapeutics key executives
Compass Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Thomas J. Schuetz M.D., Ph.D. (64) Co-Founder, Chief Executive Officer & Director
- Dr. Vered Bisker-Leib Ph.D., MBA (54) Pres & Chief Operating Officer